Research Article
Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan
Yosuke TachibanaBiogen Japan, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-5910-2296View further author information
https://orcid.org/0000-0001-5910-2296View further author information, Ryusuke SatoBiogen Japan, Tokyo, Japanhttps://orcid.org/0000-0002-7826-1978View further author information
https://orcid.org/0000-0002-7826-1978View further author information, Haruki MakiokaBiogen Japan, Tokyo, Japanhttps://orcid.org/0000-0002-8295-3723View further author information
https://orcid.org/0000-0002-8295-3723View further author information, Misuzu HoshinoBiogen Japan, Tokyo, Japanhttps://orcid.org/0000-0003-1429-9923View further author information
https://orcid.org/0000-0003-1429-9923View further author information & Mingshou JinBiogen Japan, Tokyo, Japanhttps://orcid.org/0000-0002-6966-5989View further author information
https://orcid.org/0000-0002-6966-5989View further author information